Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who ...
网页链接Viking Therapeutics recently announced it has completed patient enrollment in VANQUISH-2, its Phase 3, 78-week trial of once-weekly subcutaneous VK2735 in about 1,000 adults with type 2 diabetes who ...
网页链接免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。